Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
[HTML][HTML] Glioblastoma multiforme: an overview of emerging therapeutic targets
OG Taylor, JS Brzozowski, KA Skelding - Frontiers in oncology, 2019 - frontiersin.org
Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain
tumour in humans and has a very poor prognosis. The existing treatments have had limited …
tumour in humans and has a very poor prognosis. The existing treatments have had limited …
[HTML][HTML] Glioblastoma targeted therapy: updated approaches from recent biological insights
Glioblastoma (WHO grade IV astrocytoma) is the most frequent primary brain tumor in adults,
representing a highly heterogeneous group of neoplasms that are among the most …
representing a highly heterogeneous group of neoplasms that are among the most …
[HTML][HTML] Updated insights on EGFR signaling pathways in glioma
A Oprita, SC Baloi, GA Staicu, O Alexandru… - International journal of …, 2021 - mdpi.com
Nowadays, due to recent advances in molecular biology, the pathogenesis of glioblastoma
is better understood. For the newly diagnosed, the current standard of care is represented by …
is better understood. For the newly diagnosed, the current standard of care is represented by …
[HTML][HTML] A systematic review of glioblastoma-targeted therapies in phases II, III, IV clinical trials
E Cruz Da Silva, MC Mercier, N Etienne-Selloum… - Cancers, 2021 - mdpi.com
Simple Summary This review describes in a very detailed and exhaustive approach the
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …
[HTML][HTML] EGFR as a target for glioblastoma treatment: an unfulfilled promise
M Westphal, CL Maire, K Lamszus - CNS drugs, 2017 - Springer
The receptor for epidermal growth factor (EGFR) is a prime target for cancer therapy across
a broad variety of tumor types. As it is a tyrosine kinase, small molecule tyrosine kinase …
a broad variety of tumor types. As it is a tyrosine kinase, small molecule tyrosine kinase …
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors
Brain tumors remain one of the most difficult tumors to treat and, depending on the
diagnosis, have a poor prognosis. Of brain tumors, glioblastoma (GBM) is the most common …
diagnosis, have a poor prognosis. Of brain tumors, glioblastoma (GBM) is the most common …
Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide
K Messaoudi, A Clavreul, F Lagarce - Drug discovery today, 2015 - Elsevier
Highlights•Temozolomide resistance can be induced by glioblastoma cells.•Resistance to
temozolomide is caused by multiple mechanisms.•Different resistance pathways exist in …
temozolomide is caused by multiple mechanisms.•Different resistance pathways exist in …
[HTML][HTML] Targeting RTK-PI3K-mTOR axis in gliomas: An update
M Colardo, M Segatto, S Di Bartolomeo - International Journal of …, 2021 - mdpi.com
Gliomas are the most common and challenging malignancies of the central nervous system
(CNS), due to their infiltrative nature, tendency to recurrence, and poor response to …
(CNS), due to their infiltrative nature, tendency to recurrence, and poor response to …
EGFR as a clinical marker in glioblastomas and other gliomas
Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and a member of
the tyrosine kinase superfamily receptor. Gliomas are tumors originating from glial cells …
the tyrosine kinase superfamily receptor. Gliomas are tumors originating from glial cells …